-
公开(公告)号：US09266922B2
公开(公告)日：2016-02-23
申请号：US14122937
申请日：2012-05-31
申请人： Marc Lopez , Daniel Olive
发明人： Marc Lopez , Daniel Olive
IPC分类号： C12N5/10 , A61K35/17 , C07K7/06 , C07K14/47 , C07K14/78 , C07K16/18 , C07K14/725 , A61K39/00
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5156 , A61K2039/5158 , C07K7/06 , C07K14/4748 , C07K14/78 , C07K16/18 , C12N5/0638 , C12N2501/998 , C12N2510/00
摘要： The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
摘要翻译： 本发明涉及源自Nectin4的抗原肽及其用于预防和治疗癌症的用途。
-
公开(公告)号：US20150353643A1
公开(公告)日：2015-12-10
申请号：US14791528
申请日：2015-07-06
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395
CPC分类号： A61K39/0011 , A61K39/00 , C07K16/2818 , C07K16/2827 , C07K2317/55 , C07K2317/74 , C07K2317/75
摘要： Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
摘要翻译： 本文描述的是抗CD277抗体：除了CD28-B7共刺激之外，还激活或抑制Vγ9/Vδ2T细胞的细胞溶解功能和/或与CD3-TCR共同刺激T细胞和/或共刺激T细胞，和/ 或增加单核细胞和树突细胞的活性和/或存活。 还描述了在治疗中使用所述抗体。
-
公开(公告)号：US20140322235A1
公开(公告)日：2014-10-30
申请号：US13994277
申请日：2011-12-14
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , C07K16/2818 , C07K16/2827 , C07K2317/55 , C07K2317/73 , C07K2317/75
摘要： The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.
摘要翻译： 本发明涉及除了CD28-B7共刺激以外，还激活或抑制Vy9 /Vδ2T细胞的细胞溶解功能和/或与CD3-TCR共同刺激T细胞和/或共刺激T细胞的抗CD277抗体， 和/或增加单核细胞和树突状细胞的活性和/或存活。 本发明还涉及所述抗体在治疗中的用途。
-
公开(公告)号：US08741295B2
公开(公告)日：2014-06-03
申请号：US13148420
申请日：2010-02-09
申请人： Daniel Olive
发明人： Daniel Olive
IPC分类号： A61K39/395 , C07K16/22 , C07K16/24 , C12N5/00 , C12N5/16
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2827 , C07K2317/55 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
摘要翻译： 本发明涉及PD-1抗体和PD-L1抗体及其用途。
-
公开(公告)号：US20140086923A1
公开(公告)日：2014-03-27
申请号：US14008423
申请日：2012-03-29
IPC分类号： C07K16/28 , G01N33/569
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/28 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/57415
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
摘要翻译： 本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。 本发明还提供了针对ICOS或其衍生物的抗体，其诱导IL-10和IFNγ产生，诱导CD4 + T细胞增殖，降低Tconv增殖，并增加Treg的免疫抑制功能。
-
公开(公告)号：US20120064096A1
公开(公告)日：2012-03-15
申请号：US13255977
申请日：2010-03-16
申请人： Daniel Olive
发明人： Daniel Olive
CPC分类号： C07K16/2818 , A61K39/3955 , A61K2039/505 , C07K16/2827 , C07K16/2878 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/74 , Y02A50/386 , Y02A50/388 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466 , Y02A50/484 , Y02A50/489
摘要： The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
摘要翻译： 本发明涉及阻断BTLA-HVEM相互作用的BTLA抗体及其用途。
-
公开(公告)号：US20060186569A1
公开(公告)日：2006-08-24
申请号：US11359345
申请日：2006-02-22
申请人： Daniel Olive , Glenn Sprague , Robert Steinkraus
发明人： Daniel Olive , Glenn Sprague , Robert Steinkraus
IPC分类号： B27N3/00
CPC分类号： B29C70/46 , B29C70/025 , B29C70/086 , B29C70/66 , B29L2031/3005
摘要： A multi-composite material comprised of core filler particles encapsulated by a bonding agent. The overall composite generally includes a composite mat and bonding agent which encompasses the core composite for an integral bond and which may be finished to a Class A automotive finish. The multi-composite material is typically used for structural panels, vehicle bumpers, and like applications.
摘要翻译： 由复合材料构成的核心填料颗粒由粘合剂包封。 整体复合材料通常包括复合垫和粘合剂，其包含用于整体粘合的芯复合材料，并且可以完成到A级汽车漆。 多复合材料通常用于结构面板，车辆保险杠和类似应用。
-
公开(公告)号：US09376493B2
公开(公告)日：2016-06-28
申请号：US14008423
申请日：2012-03-29
IPC分类号： C07K16/28 , A61K39/395 , G01N33/569
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/28 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/57415
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
摘要翻译： 本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。 本发明还提供了针对ICOS或其衍生物的抗体，其诱导IL-10和IFNγ产生，诱导CD4 + T细胞增殖，降低Tconv增殖，并增加Treg的免疫抑制功能。
-
公开(公告)号：US08318166B2
公开(公告)日：2012-11-27
申请号：US12602539
申请日：2008-06-02
申请人： Daniel Olive , Alemseged Truneh , Christine Pasero
发明人： Daniel Olive , Alemseged Truneh , Christine Pasero
IPC分类号： A61K39/395
CPC分类号： C07K16/2878 , A61K38/191 , A61K39/39558 , C07K14/70575 , C07K2317/73 , C07K2317/75 , A61K2300/00
摘要： The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
摘要翻译： 本发明涉及用于治疗血液恶性肿瘤，特别是慢性淋巴细胞性白血病和用于治疗自身免疫性疾病的HVEM的配体。
-
公开(公告)号：US20200376104A1
公开(公告)日：2020-12-03
申请号：US16896556
申请日：2020-06-09
摘要： Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.026 秒)